Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling
Peter J. Siska(University Hospital Regensburg), Douglas B. Johnson(Vanderbilt University Medical Center), Romany Johnpulle(Vanderbilt University Medical Center), Bashar Dabbas(Lineage Cell Therapeutics (United States)), Jeffrey C. Rathmell(University of Chicago), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Alicia K. Morgans(Dana-Farber Cancer Institute), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Justin M. Balko(Vanderbilt University Medical Center), Alice Y. Zhou, Ju Young Kim(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States))
Cited by 83
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
|The Journal of Immunology|2011|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|867